NEUROENDOCRINE NEOPLASMS
Clinical trials for NEUROENDOCRINE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE NEOPLASMS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat neuroendocrine tumors
Disease control Recruiting nowThis study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to shrink Hard-to-Treat lung cancers
Disease control Recruiting nowThis phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Radioactive therapy targets rare tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests a radioactive drug called Lu-177-DOTATATE in 130 adults with rare adrenal or neck tumors that cannot be surgically removed. The drug is given four times over about 8 months, and researchers track how long the cancer stays under control. The goal is to see…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise for rare gut and lung tumors
Disease control Recruiting nowThis study is testing an oral drug called surufatinib in 350 adults with advanced neuroendocrine tumors (NETs). The drug works by cutting off blood supply to tumors and boosting the immune system. Researchers want to see if it helps control the disease and improves survival in re…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New imaging trial peers inside tumors to track experimental Drug's path
Knowledge-focused Recruiting nowThis study uses a special PET scan to see how the experimental drug BI 764532 travels through the body and reaches tumors. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers who have run out of standard treatment options. The main goal is to mea…
Matched conditions: NEUROENDOCRINE NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC